Haemonetics Lands Non-Exclusive Deal with Major Plasma Collector CSL
Haemonetics enters a non-exclusive supply deal with CSL Plasma for NexSys PCS devices with Persona PLUS technology and disposables in the U.S.
/ 1648 items
#XY↓
Nuvation Bio: JPMorgan Sees Strong Ibtrozi Launch and Pipeline Upside
JPMorgan initiates Nuvation Bio at Overweight with $13 target, citing durable first-line adoption of Ibtrozi in ROS1+ lung cancer.
Amylyx Drug Cuts Dangerous Low Blood Sugar Episodes After Weight-Loss Surgery in Key Trial
Amylyx’s avexitide reduced severe low blood sugar episodes by 55% in a Phase 3 trial for post-bariatric hypoglycemia. First potential treatment nears FDA filing.
Kura Oncology Insider Buy: CEO Adds $1.11M Stake as Cash Runway Stretches to 2028
Kura Oncology CEO Troy Wilson bought 100K shares for $1.11M on Aug 17, 2026. Open-market buy follows KOMZIFTI sales and cash runway to 2028.
Amylyx to Reveal Phase 3 LUCIDITY Results for Avexitide Tomorrow – Stock Jumps on Clear Timeline
Topline data from Amylyx’s Phase 3 LUCIDITY trial of avexitide for PBH arrives August 18. Prior results and unmet need fuel optimism.
B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.